VivoSeq
Gastroenterology

Intestinal Obstruction

9

Pipeline Programs↗

0

Active Trials↗

8

Companies Involved↗

Intestinal Obstruction is an early-stage landscape with 9 programs across 8 companies. The most active players are Ipsen, Scienture, Pfizer. 8 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

0/100

Mech. Concentration

13/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Ipsen logo

Ipsen

1 program

Phase 2S

Scienture

1 program

ApprovedPfizer logo

Pfizer

1 program

ApprovedK

Kenvue Brands

1 program

ApprovedSun Pharma logo

Sun Pharma

1 program

ApprovedM

Milestone Pharmaceuticals Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

73%

Small molecule

8 of 11 classified programs — the dominant modality here.

27%ALL OTHERSPeptide327%

Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 100% of 11 pipeline programs.

Analysis

Trial Status

4

clinical trials

Completed3 · 75%
Unknown status1 · 25%

Clinical Trials

Trial Activity

Comparison Between Two Concentration of Hypertonic Saline in Intestinal Obstruction Surgery
Unknown status·—·N/A·NCT03741257·50 enrolled
Efficacy and Safety of Lanreotide 120 Milligram (mg) as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients
Completed·UUniversity Hospital, Ghent·Phase 2·NCT01076803·40 enrolled
The Effect of Guardix-solution for the Prevention of Postoperative Intestinal Adhesion and Intestinal Obstruction After Laparoscopic Pelvic Cavity Surgery
Completed·—·Phase 4·NCT02773251·60 enrolled
Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction
Completed·Ipsen logoIpsen·Phase 2·NCT02275338·52 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)